152 related articles for article (PubMed ID: 37904342)
21. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
22. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
23. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.
Harmanen M; Hujo M; Sund R; Sorigue M; Khan M; Prusila R; Klaavuniemi T; Kari E; Jantunen E; Sunela K; Rajamäki A; Alanne E; Kuitunen H; Sancho JM; Jukkola A; Rönkä A; Kuittinen O
Br J Haematol; 2023 Apr; 201(1):64-74. PubMed ID: 36513500
[TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
[TBL] [Abstract][Full Text] [Related]
27. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Till BG
Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
29. Treatment of mantle cell lymphoma in older adults.
Pease DF; Morrison VA
J Geriatr Oncol; 2018 Jul; 9(4):308-314. PubMed ID: 29325898
[TBL] [Abstract][Full Text] [Related]
30. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
31. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma.
Borgerding A; Hasenkamp J; Glass B; Wulf G; Trümper L
Ann Hematol; 2010 Mar; 89(3):283-9. PubMed ID: 19727725
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
33. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
Deshpande A; Wang Y; Munoz J; Jain P
Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
[TBL] [Abstract][Full Text] [Related]
34. Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma.
Pola R; Pokorná E; Vočková P; Böhmová E; Pechar M; Karolová J; Pankrác J; Šefc L; Helman K; Trněný M; Etrych T; Klener P
Acta Biomater; 2021 Jan; 119():349-359. PubMed ID: 33186784
[TBL] [Abstract][Full Text] [Related]
35. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
37. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Bouabdallah K; Khanal R; Topp MS; Houot R; Beitinjaneh A; Peng W; Fang X; Shen RR; Siddiqi R; Kloos I; Reagan PM
J Clin Oncol; 2023 Jan; 41(3):555-567. PubMed ID: 35658525
[TBL] [Abstract][Full Text] [Related]
38. Current overview and treatment of mantle cell lymphoma.
Schieber M; Gordon LI; Karmali R
F1000Res; 2018; 7():. PubMed ID: 30109020
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
[TBL] [Abstract][Full Text] [Related]
40. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
